C-RAD AB (publ) the global leader in surface-guided radiation therapy (SGRT), and SeeTreat Pty Ltd, a pioneer in the adaptive decision support radiotherapy (ART) software, today confirm a partnership to co-develop more connected, intelligent, and patient-centric radiotherapy workflows.
In 2027, the partners will bring together two complementary technologies: C-RAD’s Catalyst⁺ HD platform, which provides patient setup and real-time motion monitoring, and SeeTreat’s ART.1, which delivers automated adaptive plan decision support for every patient at every treatment. The joint platform will support clinical teams to make faster, better-informed decisions to improve patient care.
"Radiation oncology needs connected systems, not isolated tools. That is why we are building an open workflow platform, and we are proud to welcome SeeTreat as our first partner. Together, we combine C-RAD's positioning and motion management expertise with SeeTreat's adaptive decision support, bringing us closer to a truly integrated treatment ecosystem." says Chief Executive Officer, Tomas Blomquist.
“SeeTreat’s vision is to reduce the burden of cancer at scale with integrated software technology and we’re excited to partner with C-RAD, the global leader for Surface Guided Radiation Therapy and automatic patient workflow, to accelerate realising that vision”. says CEO and Founder of SeeTreat, Dr Trang Nguyen.
Both companies share a commitment to bringing advances to radiotherapy departments of all sizes and any treatment machines — from major cancer centres to community clinics where resources may be limited, but the need for precision and efficiency is just as critical.
Clinical teams interested in learning more are invited to meet C-RAD and SeeTreat at ASTRO 2026 in Boston.